1887

Chapter 13.6 : S C

MyBook is a cheap paperback edition of the original book and will be sold at uniform, low price.

Ebook: Choose a downloadable PDF or ePub file. Chapter is a downloadable PDF file. File must be downloaded within 48 hours of purchase

Buy this Chapter
Digital (?) $30.00

Preview this chapter:
Zoom in
Zoomout

S C, Page 1 of 2

| /docserver/preview/fulltext/10.1128/9781555818814/9781555818814_Chap13.6-1.gif /docserver/preview/fulltext/10.1128/9781555818814/9781555818814_Chap13.6-2.gif
There is no abstract provided for this chapter. We are in the process of generating a full text preview. Please bookmark and return later.
Citation: Leber A. 2016. S C, p 13.6.1.1-13.6.6.17. In Clinical Microbiology Procedures Handbook, Fourth Edition. ASM Press, Washington, DC. doi: 10.1128/9781555818814.ch13.6
Highlighted Text: Show | Hide
Loading full text...

Full text loading...

References

/content/book/10.1128/9781555818814.chap13.6
1. Tübbicke A, Hübner C, Kramer A, Hübner N-O, Fleßa S. 2012. Transmission rates, screening methods and costs of MRSA—a systematic literature review related to the prevalence in Germany. Eur J Clin Microbiol Infect Dis 31:24972511.
2. Tübbicke A, Hübner C, Hübner N-O, Wegner C, Kramer A, Fleßa S. 2012. Cost comparison of MRSA screening and management - a decision tree analysis. BMC Health Serv Res 12:438.
3. Sarma JB, Marshall B, Cleeve V, Tate D, Oswald T. 2013. Impact of universal screening on MRSA bacteremias in a single acute NHS organisation (2006–12): interrupted time-series analysis. Antimicrob Resist Infect Control 2:2.
4. Huang SS, Septimus E, Kleinman K, Moody J, Hickok J, Avery TR, Lankiewicz J, Gombosev A, Terpstra L, Hartford F, Hayden MK, Jernigan JA, Weinstein RA, Fraser VJ, Haffenreffer K, Cui E, Kaganov RE, Lolans K, Perlin JB, Platt R, CDC Prevention Epicenters Program, AHRQ DECIDE Network and Healthcare-Associated Infections Program. 2013. Targeted versus universal decolonization to prevent ICU infection. N Engl J Med 368:22552265.
5. Glick SB, Samson DJ, Huang E, Vats V, Weber S, Aronson N. 2013. Screening for Methicillin-Resistant Staphylococcus aureus (MRSA). Agency for Healthcare Research and Quality, Rockville, MD.
6. McKinnell JA, Huang SS, Eells SJ, Cui E, Miller LG. 2013. Quantifying the impact of extranasal testing of body sites for methicillin-resistant Staphylococcus aureus colonization at the time of hospital or intensive care unit admission. Infect Control Hosp Epidemiol 34:161170.
7. Chen AF, Wessel CB, Rao N. 2013. Staphylococcus aureus screening and decolonization in orthopaedic surgery and reduction of surgical site infections. Clin Orthop Relat Res 471:23832399.
8. Denys GA, Renzi PB, Koch KM, Wissel CM. 2013. Three-way comparison of BBL CHROMagar MRSA II, MRSASelect, and spectra MRSA for detection of methicillin-resistant Staphylococcus aureus isolates in nasal surveillance cultures. J Clin Microbiol 51:202205.
9. Al-Talib H, Yean CY, Al-khateeb A, Singh K-KB, Hasan H, Al-Jashamy K, Ravichandran M. 2010. Comparative evaluation of five culture media with triplex PCR assay for detection of methicillin-resistant Staphylococcus aureus. Curr Microbiol 61:16.
10. Wolk DM, Marx JL, Dominguez L, Driscoll D, Schifman RB. 2009. Comparison of MRSASelect agar, CHROMagar methicillin-resistant Staphylococcus aureus (MRSA) medium, and Xpert MRSA PCR for detection of MRSA in nares: diagnostic accuracy for surveillance samples with various bacterial densities. J Clin Microbiol 47:39333936.
11. Aydiner A, Lüsebrink J, Schildgen V, Winterfeld I, Knüver O, Schwarz K, Messler S, Schildgen O, Mattner F. 2012. Comparison of two commercial PCR methods for methicillin-resistant Staphylococcus aureus (MRSA) screening in a tertiary care hospital. PLoS One 7:e43935.
12. Snyder JW, Munier GK, Johnson CL. 2010. Comparison of the BD GeneOhm methicillin-resistant Staphylococcus aureus (MRSA) PCR assay to culture by use of BBL CHROMagar MRSA for detection of MRSA in nasal surveillance cultures from intensive care unit patients. J Clin Microbiol 48:13051309.
13. Blanc DS, Nahimana I, Zanetti G, Greub G. 2013. MRSA screening by the Xpert MRSA PCR assay: pooling samples of the nose, throat, and groin increases the sensitivity of detection without increasing the laboratory costs. Eur J Clin Microbiol Infect Dis 32:565568.
1. Olivier CN, Blake RK, Steed LL, Salgado CD. 2008. Risk of vancomycin-resistant Enterococcus (VRE) bloodstream infection among patients colonized with VRE. Infect Control Hosp Epidemiol 29:404409.
2. Sakka V, Tsiodras S, Galani L, Antoniadou A, Souli M, Galani I, Pantelaki M, Siafakas N, Zerva L, Giamarellou H. 2008. Risk-factors and predictors of mortality in patients colonised with vancomycin-resistant enterococci. Clin Microbiol Infect 14:1421.
3. Price CS, Paule S, Noskin GA, Peterson LR. 2003. Active surveillance reduces the incidence of vancomycin-resistant enterococcal bacteremia. Clin Infect Dis 37:921928.
4. Escaut L, Bouam S, Frank-Soltysiak M, Rudant E, Saliba F, Kassis N, Presiozi P, Vittecoq D. 2013. Eradication of an outbreak of vancomycin-resistant Enterococcus (VRE): the cost of a failure in the systematic screening. Antimicrob Resist Infect Control 2:18.
5. Weber SG, Huang SS, Oriola S, Huskins WC, Noskin GA, Harriman K, Olmsted RN, Bonten M, Lundstrom T, Climo MW, Roghmann M-C, Murphy CL, Karchmer TB. 2007. Legislative mandates for use of active surveillance cultures to screen for methicillin-resistant Staphylococcus aureus and vancomycin-resistant enterococci: position statement from the Joint SHEA and APIC Task Force. Am J Infect Control 35:7385.
6. Diekema DJ, Edmond MB. 2007. Look before you leap: active surveillance for multidrug-resistant organisms. Clin Infect Dis 44:11011107.
7. Weddle G, Jackson MA, Selvarangan R. 2012. Utility of a focused vancomycin-resistant enterococci screening protocol to identify colonization in hospitalized children. Am J Infect Control 40:891892.
8. Reisner BS, Shaw S, Huber ME, Woodmansee CE, Costa S, Falk PS, Mayhall CG. 2000. Comparison of three methods to recover vancomycin-resistant enterococci (VRE) from perianal and environmental samples collected during a hospital outbreak of VRE. Infect Control Hosp Epidemiol 21:775779.
9. Grabsch EA, Ghaly-Derias S, Gao W, Howden BP. 2008. Comparative study of selective chromogenic (chromID VRE) and bile esculin agars for isolation and identification of vanB-containing vancomycin-resistant enterococci from feces and rectal swabs. J Clin Microbiol 46:40344036.
10. Klare I, Fleige C, Geringer U, Witte W, Werner G. 2012. Performance of three chromogenic VRE screening agars, two Etest(®) vancomycin protocols, and different microdilution methods in detecting vanB genotype Enterococcus faecium with varying vancomycin MICs. Diagn Microbiol Infect Dis 74:171176.
11. Stamper PD, Shulder S, Bekalo P, Manandhar D, Ross TL, Speser S, Kingery J, Carroll KC. 2010. Evaluation of BBL CHROMagar VanRE for detection of vancomycin-resistant enterococci in rectal swab specimens. J Clin Microbiol 48:42944297.
12. Anderson NW, Buchan BW, Young CL, Newton DW, Brenke C, Lapsley L, Granato PA, Ledeboer NA. 2013. Multicenter clinical evaluation of VRESelect agar for identification of vancomycin-resistant Enterococcus faecalis and Enterococcus faecium. J Clin Microbiol 51:27582760.
13. Stamper PD, Cai M, Lema C, Eskey K, Carroll KC. 2007. Comparison of the BD GeneOhm VanR assay to culture for identification of vancomycin-resistant enterococci in rectal and stool specimens. J Clin Microbiol 45:33603365.
14. Palladino S, Kay ID, Flexman JP, Boehm I, Costa AMG, Lambert EJ, Christiansen KJ. 2003. Rapid detection of vanA and vanB genes directly from clinical specimens and enrichment broths by real-time multiplex PCR assay. J Clin Microbiol 41:24832486.
15. Mak A, Miller MA, Chong G, Monczak Y. 2009. Comparison of PCR and culture for screening of vancomycin-resistant enterococci: highly disparate results for vanA and vanB. J Clin Microbiol 47:41364137.
16. Fang H, Ohlsson A-K, Jiang G-X, Ullberg M. 2012. Screening for vancomycin-resistant enterococci: an efficient and economical laboratory-developed test. Eur J Clin Microbiol Infect Dis 31:261265.
1. Paterson DL. 2006. Resistance in gram-negative bacteria: Enterobacteriaceae. Am J Infect Control 34:S20S28; discussion, S64– S73.
2. Woodford N, Ellington MJ, Coelho JM, Turton JF, Ward ME, Brown S, Amyes SG, Livermore DM. 2006. Multiplex PCR for genes encoding prevalent OXA carbapenemases in Acinetobacter spp. Int J Antimicrob Agents 27:351353.
3. Jacoby GA, Munoz-Price LS. 2005. The new beta-lactamases. N Engl J Med 352:380391.
4. Nordmann P, Naas T, Poirel L. 2011. Global spread of carbapenemase-producing Enterobacteriaceae. Emerg Infect Dis 17:17911798.
5. Poirel L, Potron A, Nordmann P. 2012. OXA-48-like carbapenemases: the phantom menace. J Antimicrob Chemother 67:15971606.
6. Gazin M, Paasch F, Goossens H, Malhotra-Kumar S. 2012. Current trends in culture-based and molecular detection of extended-spectrum-beta-lactamase-harboring and carbapenem-resistant Enterobacteriaceae. J Clin Microbiol 50:11401146.
7. Centers for Disease Control and Prevention. 2012. Guidance for the control of carbapenem-resistant Enterobacteriaceae (CRE). 2012 Toolkit. Centers for Disease Control and Prevention, Atlanta, GA.
8. Avlami A, Bekris S, Ganteris G, Kraniotaki E, Malamou-Lada E, Orfanidou M, Paniara O, Pantazatou A, Papagiannitsis CC, Platsouka E, Stefanou I, Tzelepi E, Vagiakou H, Miriagou V. 2010. Detection of metallo-beta-lactamase genes in clinical specimens by a commercial multiplex PCR system. J Microbiol Methods 83:185187.
1. Salgado CD, Farr BM, Hall KK, Hayden FG. 2002. Influenza in the acute hospital setting. Lancet Infect Dis 2:145155.
2. Hota S, McGeer A. 2007. Antivirals and the control of influenza outbreaks. Clin Infect Dis 45:13621368.
3. Siegel JD, Rhinehart E, Jackson M, Chiarello L, Health Care Infection Control Practices Advisory Committee. 2007. 2007 guideline for isolation precautions: preventing transmission of infectious agents in health care settings. Am J Infect Control 35(10 Suppl 2):S65S164.
4. Harper SA, Bradley JS, Englund JA, File TM, Gravenstein S, Hayden FG, McGeer AJ, Neuzil KM, Pavia AT, Tapper ML, Uyeki TM, Zimmerman RK, Expert Panel of the Infectious Diseases Society of America. 2009. Seasonal influenza in adults and children—diagnosis, treatment, chemoprophylaxis, and institutional outbreak management: clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis 48:10031032.
5. Fiore AE, Fry A, Shay D, Gubareva L, Bresee JS, Uyeki TM, Centers for Disease Control and Prevention (CDC). 2011. Antiviral agents for the treatment and chemoprophylaxis of influenza—recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recommend Rep 60:124.
6. Casper C, Englund J, Boeckh M. 2010. How I treat influenza in patients with hematologic malignancies. Blood 115:13311342.
7. Chartrand C, Leeflang MM, Minion J, Brewer T, Pai M. 2012. Accuracy of rapid influenza diagnostic tests: a meta-analysis. Ann Intern Med 156:500511.
8. Prendergast C, Papenburg J. 2013. Rapid antigen-based testing for respiratory syncytial virus: moving diagnostics from bench to bedside? Future Microbiol 8:435444.
9. Esposito S, Molteni CG, Daleno C, Valzano A, Tagliabue C, Galeone C, Milani G, Fossali E, Marchisio P, Principi N. 2010. Collection by trained pediatricians or parents of mid-turbinate nasal flocked swabs for the detection of influenza viruses in childhood. Virol J 7:85.
10. Robinson JL, Lee BE, Kothapalli S, Craig WR, Fox JD. 2008. Use of throat swab or saliva specimens for detection of respiratory viruses in children. Clin Infect Dis 46:e61e64.
11. Scansen KA, Bonsu BK, Stoner E, Mack K, Salamon D, Leber A, Marcon MJ. 2010. Comparison of polyurethane foam to nylon flocked swabs for collection of secretions from the anterior nares in performance of a rapid influenza virus antigen test in a pediatric emergency department. J Clin Microbiol 48:852856.
12. Myers C, Wagner N, Kaiser L, Posfay-Barbe K, Gervaix A. 2008. Use of the rapid antigenic test to determine the duration of isolation in infants hospitalized for respiratory syncytial virus infections. Clin Pediatr (Phila) 47:493495.
13. Mills JM, Harper J, Broomfield D, Templeton KE. 2011. Rapid testing for respiratory syncytial virus in a paediatric emergency department: benefits for infection control and bed management. J Hosp Infect 77:248251.
14. Zorc JJ, Hall CB. 2010. Bronchiolitis: recent evidence on diagnosis and management. Pediatrics 125:342349.
15. Vallières E, Renaud C. 2013. Clinical and economical impact of multiplex respiratory virus assays. Diagn Microbiol Infect Dis 76:255261.
16. Goins WP, Talbot HK, Talbot TR. 2011. Health care-acquired viral respiratory diseases. Infect Dis Clin North Am 25:227244.
1. Diekema DJ, Edmond MB. 2007. Look before you leap: active surveillance for multidrug-resistant organisms. Clin Infect Dis 44:11011107.
2. Harrington G, Watson K, Bailey M, Land G, Borrell S, Houston L, Kehoe R, Bass P, Cockroft E, Marshall C, Mijch A, Spelman D. 2007. Reduction in hospitalwide incidence of infection or colonization with methicillin-resistant Staphylococcus aureus with use of antimicrobial hand-hygiene gel and statistical process control charts. Infect Control Hosp Epidemiol 28:837844.
3. McGinigle KL, Gourlay ML, Buchanan IB. 2008. The use of active surveillance cultures in adult intensive care units to reduce methicillin-resistant Staphylococcus aureus-related morbidity, mortality, and costs: a systematic review. Clin Infect Dis 46:17171725.
4. Peterson LR, Diekema DJ. 2010. To screen or not to screen for methicillin-resistant Staphylococcus aureus. J Clin Microbiol 48:683689.
5. Robicsek A, Beaumont JL, Paule SM, Hacek DM, Thomson RBJr, Kaul KL, King P, Peterson LR. 2008. Universal surveillance for methicillin-resistant Staphylococcus aureus in 3 affiliated hospitals. Ann Intern Med 148:409418.
6. Tacconelli E, De Angelis G, de Waure C, Cataldo MA, La Torre G, Cauda R. 2009. Rapid screening tests for meticillin-resistant Staphylococcus aureus at hospital admission: systematic review and meta-analysis. Lancet Infect Dis 9:546554.
7. Tokars JI, Richards C, Andrus M, Klevens M, Curtis A, Horan T, Jernigan J, Cardo D. 2004. The changing face of surveillance for health care-associated infections. Clin Infect Dis 39:13471352.
8. Duffy J, Sievert D, Rebmann C, Kainer M, Lynfield R, Smith P, Fridkin S. 2011. Effective state-based surveillance for multidrug-resistant organisms related to health care-associated infections. Public Health Rep 126:176184.
9. Meier BM, Stone PW, Gebbie KM. 2008. Public health law for the collection and reporting of health care-associated infections. Am J Infect Control 36:537551.
10. Weber SG, Huang SS, Oriola S, Huskins WC, Noskin GA, Harriman K, Olmsted RN, Bonten M, Lundstrom T, Climo MW, Roghmann MC, Murphy CL, Karchmer TB. 2007. Legislative mandates for use of active surveillance cultures to screen for methicillin-resistant Staphylococcus aureus and vancomycin-resistant enterococci: position statement from the Joint SHEA and APIC Task Force. Am J Infect Control 35:7385.
11. The White House. March 2015. National action plan for combating antibiotic-resistant bacteria. https://www.whitehouse.gov/sites/default/files/docs/national_action_plan_for_combating_antibotic-resistant_bacteria.pdf. The White House, Washington, DC. Accessed 18 September 2015.
12. McKinnell JA, Huang SS, Eells SJ, Cui E, Miller LG. 2013. Quantifying the impact of extranasal testing of body sites for methicillin-resistant Staphylococcus aureus colonization at the time of hospital or intensive care unit admission. Infect Control Hosp Epidemiol 34:161170.
13. Snyder GM, D’Agata EMC. 2012. Diagnostic accuracy of surveillance cultures to detect gastrointestinal colonization with multidrug-resistant gram-negative bacteria. Am J Infect Control 40:474476.
14. Snyder GM, O’Fallon E, D’Agata EM. 2011. Co-colonization with multiple different species of multidrug-resistant gram-negative bacteria. Am J Infect Control 39:506510.
15. Edmond MB, Ober JF, Bearman G. 2008. Active surveillance cultures are not required to control MRSA infections in the critical care setting. Am J Infect Control 36:461463.
16. Harbarth S, Fankhauser C, Schrenzel J, Christenson J, Gervaz P, Bandiera-Clerc C, Renzi G, Vernaz N, Sax H, Pittet D. 2008. Universal screening for methicillin-resistant Staphylococcus aureus at hospital admission and nosocomial infection in surgical patients. JAMA 299:11491157.
17. Kang J, Mandsager P, Biddle AK, Weber DJ. 2012. Cost-effectiveness analysis of active surveillance screening for methicillin-resistant Staphylococcus aureus in an academic hospital setting. Infect Control Hosp Epidemiol 33:477486.
18. Lee BY, Bailey RR, Smith KJ, Muder RR, Strotmeyer ES, Lewis GJ, Ufberg PJ, Song Y, Harrison LH. 2010. Universal methicillin-resistant Staphylococcus aureus (MRSA) surveillance for adults at hospital admission: an economic model and analysis. Infect Control Hosp Epidemiol 6:598606.
19. Vendettuoli V, Tana M, Tirone C, Posteraro B, La Sorda M, Fadda G, Romagnoli C, Vento G. 2008. The role of Candida surveillance cultures for identification of a preterm subpopulation at highest risk for invasive fungal infection. Ped Infect Dis Journal 27:11141116.
20. Youngster I, Sharma T, Duncan C, Mc-Adam A. 2013. The yield of fungal surveillance cultures in pediatric hematopoietic stem cell transplant patients: a retrospective analysis and survey of current practice. Clin Infect Dis 58:365371.
1. Center for International Blood and Marrow Transplant Research (CIBMTR), National Marrow Donor Program (NMDP), European Blood and Marrow Transplant Group (EBMT), American Society of Blood and Marrow Transplantation (ASBMT), Canadian Blood and Marrow Transplant Group (CBMTG), Infectious Disease Society of America (IDSA), Society for Healthcare Epidemiology of America (SHEA), Association of Medical Microbiology and Infectious Diseases Canada (AMMI), Centers for Disease Control and Prevention (CDC). 2009. Guidelines for preventing infectious complications among hematopoietic cell transplant recipients: a global perspective. Bone Marrow Transplant 44(8):453558.
2. Fischer SA, Lu K, AST Infectious Diseases Community of Practice. 2013. Screening of donor and recipient in solid organ transplantation. Am J Transplant 13(Suppl 4):921.
3. Seem DL, Lee I, Umscheid CA, Kuehnert MJ. 2013. PHS guideline for reducing human immunodeficiency virus, hepatitis B virus and hepatitis C virus transmission through organ transplantation. Public Health Rep 128:247304.
4. Organ Procurement and Transplant Network. Identification of Transmissible Diseases in Organ Recipients. Policy 4. Organ Procurement and Transplant Network, Richmond, VA. http://optn.transplant.hrsa.gov/policiesandbylaws2/policies/pdfs/policy_16.pdf. Accessed June 2013.
5. US Food and Drug Administration. FDA Guidance for Industry: Eligibility Determination for Donors of Human Cells, Tissues, and Cellular and Tissue-Based Products. US FDA, Silver Spring, MD. http://www.fda.gov/biologicsbloodvaccines/guidancecompliance regulatoryinformation/guidances/tissue/ucm073964.htm. Accessed June 2013.
6. US Food and Drug Administration. Complete List of Donor Screening Assays for Infectious Agents and HIV Diagnostic Assays. US FDA, Silver Spring, MD. http://www.fda.gov/BiologicsBloodVaccines/BloodBlood Products/ApprovedProducts/Licensed ProductsBLAs/BloodDonorScreening/InfectiousDisease/UCM080466. Accessed June 2013.
7. Fishman JA, Greenwald MA, Grossi PA. 2012. Transmission of infection with human allografts: essential considerations in donor screening. Clin Infect Dis 55:720727.
8. Ison MG, Grossi P, AST Infectious Diseases Community of Practice. 2013. Donor-derived infections in solid organ transplantation. Am J Transplant 13(Suppl 4):2230.
9. Centers for Disease Control and Prevention. 2011. HIV transmitted from a living organ donor—New York City, 2009. MMWR Morb Mortal Wkly Rep 60(10):297301.
10. Eastlund T. 2000. Hemodilution due to blood loss and transfusion and reliability of cadaver tissue donor infectious disease testing. Cell Tissue Bank 1:121127.
11. Centers for Disease Control and Prevention. 2003. Hepatitis C virus transmission from an antibody-negative organ and tissue donor—United States, 2000–2002. MMWR Morb Mortal Wkly Rep 52(13):273274, 276.
12. Theodoropoulos N, Jaramillo A, Ladner DP, Ison MG. 2013. Deceased organ donor screening for HIV, hepatitis B, and hepatitis C viruses: a survey of organ procurement organization practices. Am J Transplant 13(8):21862190.
13. Humar A, Morris M, Blumberg E, Freeman R, Preiksaitis J, Kiberd B, Schweitzer E, Ganz S, Caliendo A, Orlowski JP, Wilson B, Kotton C, Michaels M, Kleinman S, Geier S, Murphy B, Green M, Levi M, Knoll G, Segev D, Brubaker S, Hasz R, Lebovitz DJ, Mulligan D, O’Connor K, Pruett T, Mozes M, Lee I, Delmonico F, Fischer S. 2010. Nucleic acid testing (NAT) of organ donors: is the ‘best’ test the right test? A consensus conference report. Am J Transplant 10(4):889899.
14. Grat M, Ligocka J, Lewandowski Z, Barski K, Holowko W, Skalski M, Kornasiewicz O, Usarek P, Zieniewicz K, Mlynarczyk G, Krawczyk M. 2012. Incidence, pattern and clinical relevance of microbial contamination of preservation fluid in liver transplantation. Ann Transplant 17(3):2028.
15. Kamble R, Pant S, Selby GB, Kharfan-Dabaja MA, Sethi S, Kratochvil K, Kohrt N, Ozer H. 2005. Microbial contamination of hematopoietic progenitor cell grafts—incidence, clinical outcome, and cost-effectiveness: an analysis of 735 grafts. Transfusion 45:874878.
16. Veroux M, Corona D, Scriffignano V, Caglia P, Gagliano M, Giuffrida G, Gona F, Sciacca A, Giaquinta A, Oliveri S, Sinagra N, Tallarita T, Zerbo D, Sorbello M, Parrinello L, Veroux P. 2010. Contamination of preservation fluid in kidney transplantation: single-center analysis. Transplant Proc 42:10431045.
17. Doig RL, Boyd PJ, Eykyn S. 1975. Staphylococcus aureus transmitted in transplanted kidneys. Lancet ii:243245.
18. Dowling RD, Baladi N, Zenati M, Dummer JS, Kormos RL, Armitage JM, Yousem SA, Hardesty RL, Griffith BP. 1990. Disruption of the aortic anastomosis after heart-lung transplantation. Ann Thorac Surg 49:118122.
19. Nelson PW, Delmonico FL, Tolkoff-Rubin NE, Cosimi AB, Fang LS, Russell PS, Rubin RH. 1984. Unsuspected donor pseudomonas infection causing arterial disruption after renal transplantation. Transplantation 37:313314.
20. Freeman RB, Giatras I, Falagas ME, Supran S, O’Connor K, Bradley J, Snydman DR, Delmonico FL. 1999. Outcome of transplantation of organs procured from bacteremic donors. Transplantation 68:11071111.
21. Ruiz I, Gavalda J, Monforte V, Len O, Roman A, Bravo C, Ferrer A, Tenorio L, Roman F, Maestre J, Molina I, Morell F, Pahissa A. 2006. Donor-to-host transmission of bacterial and fungal infections in lung transplantation. Am J Transplant 6(1):178182.
22. Centers for Disease Control and Prevention. 2011. Discordant results from reverse sequence syphilis screening—five laboratories, United States, 2006–2010. MMWR Morb Mortal Wkly Rep 60(5):133137.
23. Au WY, Lie AK, Cheng VC. 2005. VDRL screening and haemopoietic stem cell transplantation. Bone Marrow Transplant 35(10):10271028.
24. Caballero F, Domingo P, Rabella N, Lopez-Navidad A. 1998. Successful transplantation of organs retrieved from a donor with syphilis. Transplantation 65:598599.
25. Gibel LJ, Sterling W, Hoy W, Harford A. 1987. Is serological evidence of infection with syphilis a contraindication to kidney donation? Case report and review of the literature. J Urol 138:12261227.
26. Ko WJ, Chu SH, Lee YH, Lee PH, Lee CJ, Chao SH, Chang SC. 1998. Successful prevention of syphilis transmission from a multiple organ donor with serological evidence of syphilis. Transplant Proc 30:36673668.
27. Cortes NJ, Afzali B, MacLean D, Goldsmith DJ, O’Sullivan H, Bingham J, Lewis DA, MacMahon E, Tong CY, Koffman G. 2006. Transmission of syphilis by solid organ transplantation. Am J Transplant 6(10):24972499.
28. Pantanowitz L, Telford SR, Cannon ME. 2002. Tick-borne diseases in transfusion medicine. Transfus Med 12:85106.
29. AABB. 2012. Standards for Blood Banks and Transfusion Services, 28th ed. AABB, Bethesda, MD.
30. Morris MI, Daly JS, Blumberg E, Kumar D, Sester M, Schluger N, Kim SH, Schwartz BS, Ison MG, Humar A, Singh N, Michaels M, Orlowski JP, Delmonico F, Pruett T, John GT, Kotton CN. 2012. Diagnosis and management of tuberculosis in transplant donors: a donor-derived infections consensus conference report. Am J Transplant 12(9):22882300.
31. Singh N, Paterson DL. 1998. Mycobacterium tuberculosis infection in solid-organ transplant recipients: impact and implications for management. Clin Infect Dis 27:12661277.
32. Coll E, Torre-Cisneros J, Calvo R, Garrido G, Matesanz R. 14 June 2013. Incidence of tuberculosis in deceased-organ donors and transmission risk to recipients in Spain. Transplantation doi:10.1097/TP.0b013e3182977 adf.
33. Blair JE, Mulligan DC. 2007. Coccidioidomycosis in healthy persons evaluated for liver or kidney donation. Transpl Infect Dis 9:7882.
34. Singh N, Huprikar S, Burdette SD, Morris MI, Blair JE, Wheat LJ. 2012. Donor-derived fungal infections in organ transplant recipients: guidelines of the American Society of Transplantation, Infectious Diseases Community of Practice. Am J Transplant 12(9):24142428.
35. Pappagianis D, Zimmer BL. 1990. Serology of coccidioidomycosis. Clin Microbiol Rev 3::247268.
36. Edwards LB, Acquaviva FA, Livesay VT. 1973. Further observations on histoplasmin sensitivity in the United States. Am J Epidemiol 98:315325.
37. Edwards LB, Acquaviva FA, Livesay VT, Cross FW, Palmer CE. 1969. An atlas of sensitivity to tuberculin, PPD-B, and histoplasmin in the United States. Am Rev Respir Dis 99(4 Suppl):1132.
38. Wheat J, French ML, Kohler RB, Zimmerman SE, Smith WR, Norton JA, Eitzen HE, Smith CD, Slama TG. 1982. The diagnostic laboratory tests for histoplasmosis: analysis of experience in a large urban outbreak. Ann Intern Med 97:680685.
39. Baddley JW, Schain DC, Gupte AA, Lodhi SA, Kayler LK, Frade JP, Lockhart SR, Chiller T, Bynon JSJr, Bower WA. 2011. Transmission of Cryptococcus neoformans by organ transplantation. Clin Infect Dis 52(4):e94e98.
40. Sun HY, Alexander BD, Lortholary O, Dromer F, Forrest GN, Lyon GM, Somani J, Gupta KL, del Busto R, Pruett TL, Sifri CD, Limaye AP, John GT, Klintmalm GB, Pursell K, Stosor V, Morris MI, Dowdy LA, Munoz P, Kalil AC, Garcia-Diaz J, Orloff SL, House AA, Houston SH, Wray D, Huprikar S, Johnson LB, Humar A, Razonable RR, Fisher RA, Husain S, Wagener MM, Singh N, Cryptococcal Collaborative Transplant Study Group. 2010. Unrecognized pretransplant and donor-derived cryptococcal disease in organ transplant recipients. Clin Infect Dis 51:10621069.
41. Franco-Paredes C, Jacob JT, Hidron A, Rodriguez-Morales AJ, Kuhar D, Caliendo AM. 2010. Transplantation and tropical infectious diseases. Int J Infect Dis 14(3):e189e196.
42. Martin-Davila P, Fortun J, Lopez-Velez R, Norman F, Montes de Oca M, Zamarron P, Gonzalez MI, Moreno A, Pumarola T, Garrido G, Candela A, Moreno S. 2008. Transmission of tropical and geographically restricted infections during solid-organ transplantation. Clin Microbiol Rev 21:6096.
43. Bern C, Montgomery SP, Katz L, Caglioti S, Stramer SL. 2008. Chagas disease and the US blood supply. Curr Opin Infect Dis 21:476482.
44. Chin-Hong PV, Schwartz BS, Bern C, Montgomery SP, Kontak S, Kubak B, Morris MI, Nowicki M, Wright C, Ison MG. 2011. Screening and treatment of Chagas disease in organ transplant recipients in the United States: recommendations from the Chagas in Transplant Working Group. Am J Transplant 11(4):672680.
45. Gourishankar S, Doucette K, Fenton J, Purych D, Kowalewska-Grochowska K, Preiksaitis J. 2008. The use of donor and recipient screening for toxoplasma in the era of universal trimethoprim sulfamethoxazole prophylaxis. Transplantation 85:980985.
46. Delmonico FL, Snydman DR. 1998. Organ donor screening for infectious diseases: review of practice and implications for transplantation. Transplantation 65:603610.
47. Centers for Disease Control and Prevention. 2011. HIV-2 infection surveillance— United States, 1987–2009. MMWR Morb Mortal Wkly Rep 60(29):985988.
48. Gessain A, Cassar O. 2012. Epidemiological aspects and world distribution of HTLV-1 infection. Front Microbiol 3:388.
49. United Network of Organ Sharing/Organ Procurement and Transplant Network. Guidance for HTLV-1 Screening and Confirmation in Potential Donors and Reporting Potential HTLV-1 Infection. United Network of Organ Sharing/Organ Procurement and Transplant Network, Richmond, VA. http://optn.transplant.hrsa.gov/PublicComment/pubcommentPropSub_252.pdf. Accessed June 2013.
50. Strasser SI, McDonald GB. 1999. Hepatitis viruses and hematopoietic cell transplantation: a guide to patient and donor management. Blood 93:11271136.
51. Pereira BJ, Wright TL, Schmid CH, Bryan CF, Cheung RC, Cooper ES, Hsu H, Heyn-Lamb R, Light JA, Norman DJ, Van Thiel DH, Werner BG, Wright CE, Levey AS. 1994. Screening and confirmatory testing of cadaver organ donors for hepatitis C virus infection: a U.S. national collaborative study. Kidney Int 46:886892.
52. Delmonico FL. 2000. Cadaver donor screening for infectious agents in solid organ transplantation. Clin Infect Dis 31:781786.
53. Ison MG, Llata E, Conover CS, Friedewald JJ, Gerber SI, Grigoryan A, Heneine W, Millis JM, Simon DM, Teo CG, Kuehnert MJ, HIV-HCV Transplantation Transmission Investigation Team. 2011. Transmission of human immunodeficiency virus and hepatitis C virus from an organ donor to four transplant recipients. Am J Transplant 11(6):12181225.
54. Kamili S, Drobeniuc J, Araujo AC, Hayden TM. 2012. Laboratory diagnostics for hepatitis C virus infection. Clin Infect Dis 55(Suppl 1):S43S48.
55. Kumar D, Morris MI, Kotton CN, Fischer SA, Michaels MG, Allen U, Blumberg EA, Green M, Humar A, Ison MG, AST Infectious Diseases Community of Practice and Transplant Infectious Diseases Section of TTS. 2010. Guidance on novel influenza A/H1N1 in solid organ transplant recipients. Am J Transplant 10(1):1825.
56. Kotton CN. 2007. Zoonoses in solid-organ and hematopoietic stem cell transplant recipients. Clin Infect Dis. 44:857866.
57. Murray S, Charbeneau J, Marshall BC, LiPuma JJ. 2008. Impact of burkholderia infection on lung transplantation in cystic fibrosis. Am J Respir Crit Care Med 178:363371.
58. Olland A, Falcoz PE, Kessler R, Massard G. 2011. Should cystic fibrosis patients infected with Burkholderia cepacia complex be listed for lung transplantation? Interact Cardiovasc Thorac Surg 13:631634.
59. Singh N, Squier C, Wannstedt C, Keyes L, Wagener MM, Cacciarelli TV. 2006. Impact of an aggressive infection control strategy on endemic Staphylococcus aureus infection in liver transplant recipients. Infect Control Hosp Epidemiol. 27:122126.
60. Tom TS, Kruse MW, Reichman RT. 2009. Update: methicillin-resistant Staphylococcus aureus screening and decolonization in cardiac surgery. Ann Thorac Surg 88:695702.
61. Workowski KA, Berman S, Centers for Disease Control and Prevention. 2010. Sexually transmitted diseases treatment guidelines, 2010. MMWR Recomm Rep. 59(RR-12):1110.
62. Mazurek GH, Jereb J, Vernon A, LoBue P, Goldberg S, Castro K, Committee IE, Centers for Disease Control and Prevention. 2010. Updated guidelines for using interferon gamma release assays to detect Mycobacterium tuberculosis infection—United States, 2010. MMWR Recommend Rep. 59(RR-5):125.
63. Menzies D, Pai M, Comstock G. 2007. Meta-analysis: new tests for the diagnosis of latent tuberculosis infection: areas of uncertainty and recommendations for research. Ann Intern Med 146:340354.
64. Huang HC, Weigt SS, Derhovanessian A, Palchevskiy V, Ardehali A, Saggar R, Saggar R, Kubak B, Gregson A, Ross DJ, Lynch JPIII, Elashoff R, Belperio JA. 2011. Non-tuberculous mycobacterium infection after lung transplantation is associated with increased mortality. J Heart Lung Transplant 30:790798.
65. Keating MR, Daly JS, AST Infectious Diseases Community of Practice. 2013. Nontuberculous mycobacterial infections in solid organ transplantation. Am J Transplant 13(Suppl 4):7782.
66. Blair JE. 2008. Approach to the solid organ transplant patient with latent infection and disease caused by Coccidioides species. Curr Opin Infect Dis 21:415420.
67. Vail GM, Young RS, Wheat LJ, Filo RS, Cornetta K, Goldman M. 2002. Incidence of histoplasmosis following allogeneic bone marrow transplant or solid organ transplant in a hyperendemic area. Transpl Infect Dis 4:148151.
68. Luong ML, Morrissey O, Husain S. 2010. Assessment of infection risks prior to lung transplantation. Curr Opin Infect Dis 23:578583.
69. Avery RK. 2002. Recipient screening prior to solid-organ transplantation. Clin Infect Dis 35:15131519.
70. Altclas J, Sinagra A, Dictar M, Luna C, Veron MT, De Rissio AM, Garcia MM, Salgueira C, Riarte A. 2005. Chagas disease in bone marrow transplantation: an approach to preemptive therapy. Bone Marrow Transplant 36:123129.
71. Derouin F, Pelloux H, ESCMID Study Group on Clinical Parasitology. 2008. Prevention of toxoplasmosis in transplant patients. Clin Microbiol Infect 14:10891101.
72. Mulanovich VE, Ahmed SI, Ozturk T, Khokhar FA, Kontoyiannis DP, de Lima M. 2011. Toxoplasmosis in allo-SCT patients: risk factors and outcomes at a transplantation center with a low incidence. Bone Marrow Transplant 46:273277.
73. Slavin MA. 2010. Toxoplasmosis and allogeneic stem cell transplantation: can we do better? Leuk Lymphoma 51:13951396.
74. Mejia R, Nutman TB. 2012. Screening, prevention, and treatment for hyperinfection syndrome and disseminated infections caused by Strongyloides stercoralis. Curr Opin Infect Dis 25:458463.
75. Centers for Disease Control and Prevention. 2013. Transmission of Strongyloides stercoralis through transplantation of solid organs—Pennsylvania, 2012. MMWR Morb Mortal Wkly Rep 62:264266.
76. Ison MG, Nalesnik MA. 2011. An update on donor-derived disease transmission in organ transplantation. Am J Transplant 11(6):11231130.

Tables

Generic image for table
Commercially available FDA-approved influenza virus and RSV rapid antigenic assays

Commercially available FDA-approved influenza virus and RSV rapid antigenic assays

Citation: Leber A. 2016. S C, p 13.6.1.1-13.6.6.17. In Clinical Microbiology Procedures Handbook, Fourth Edition. ASM Press, Washington, DC. doi: 10.1128/9781555818814.ch13.6
Generic image for table
Commercially available FDA-approved respiratory virus immunofluorescence MAbs

Commercially available FDA-approved respiratory virus immunofluorescence MAbs

Citation: Leber A. 2016. S C, p 13.6.1.1-13.6.6.17. In Clinical Microbiology Procedures Handbook, Fourth Edition. ASM Press, Washington, DC. doi: 10.1128/9781555818814.ch13.6
Generic image for table
Commercially available FDA-approved nucleic acid amplification assays for influenza virus, RSV, and other respiratory viruses

Commercially available FDA-approved nucleic acid amplification assays for influenza virus, RSV, and other respiratory viruses

Citation: Leber A. 2016. S C, p 13.6.1.1-13.6.6.17. In Clinical Microbiology Procedures Handbook, Fourth Edition. ASM Press, Washington, DC. doi: 10.1128/9781555818814.ch13.6
Generic image for table
Table 13.6.6–1

Summary of potential donor-derived infections reported to the U.S. Organ Procurement and Transplantation Network, 2005 to 2011

Citation: Leber A. 2016. S C, p 13.6.1.1-13.6.6.17. In Clinical Microbiology Procedures Handbook, Fourth Edition. ASM Press, Washington, DC. doi: 10.1128/9781555818814.ch13.6
Generic image for table
Table 13.6.6–2

Common screening tests for transplant donors and recipients

Citation: Leber A. 2016. S C, p 13.6.1.1-13.6.6.17. In Clinical Microbiology Procedures Handbook, Fourth Edition. ASM Press, Washington, DC. doi: 10.1128/9781555818814.ch13.6

This is a required field
Please enter a valid email address
Please check the format of the address you have entered.
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error